ArticleDrug metabolism and disposition: the biological fate of chemicals2019
Brain Distribution of a Panel of Epidermal Growth Factor Receptor Inhibitors Using Cassette Dosing in Wild-Type and
Open access · bronzeAbstract read
In one paragraph
Article in Drug metabolism and disposition: the biological fate of chemicals, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 49 citations in OpenAlex.
- Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.ESMO open · 2023Trial
- Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.The oncologist · 2021Trial
- Dacomitinib for EGFR-L858R-mutated non-small cell lung cancer following acquired resistance to third-generation EGFR-TKIs: a retrospective real-world study.Translational lung cancer research · 2026Article
- Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare ofThe journal of liquid biopsy · 2025Article
- Bypassing Blood-Brain Barrier and Glucose Dependency of Anti-Glioblastoma Drug Candidates Targeting Mitochondrial Respiration.Journal of cellular physiology · 2025Article
- Central nervous system distributional kinetics of selected histone deacetylase inhibitors.The Journal of pharmacology and experimental therapeutics · 2025Article
- Preclinical evaluation of targeted therapies for central nervous system metastases.Disease models & mechanisms · 2024Review
- In silico transcriptome screens identify epidermal growth factor receptor inhibitors as therapeutics for noise-induced hearing loss.Science advances · 2024Article
- ABCG2 Mediates Resistance to the Dual EGFR and PI3K Inhibitor MTX-211 in Cancer Cells.International journal of molecular sciences · 2024Article
- How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors.Pharmaceutical research · 2023Review
- Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells.Cell death discovery · 2023Article
- ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery.Pharmacological reviews · 2023Review
- The treatment of patients with non-small cell lung cancer carrying uncommonTranslational cancer research · 2023Review
- The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.Cancer research and treatment · 2023Article
- Advances in the management of non-small-cell lung cancer harbouringTherapeutic advances in medical oncology · 2023Review
- EGFR, the Lazarus target for precision oncology in glioblastoma.Neuro-oncology · 2022Review
- Repurposed anti-cancer epidermal growth factor receptor inhibitors: mechanisms of neuroprotective effects in Alzheimer's disease.Neural regeneration research · 2022Review
- The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.Cellular oncology (Dordrecht, Netherlands) · 2022Article
- Blood-brain barrier penetration prediction enhanced by uncertainty estimation.Journal of cheminformatics · 2022Article
- Therapeutic Options in Neuro-Oncology.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Minjee KimBrain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy (M.K., J.K.L., A.S.M., S.T., W.F.E.) and Clinical Pharmacology and Analytical Services Laboratory, Department of Experimental and Clinical Pharmacology (J.F.), University of Minnesota, Minneapolis, Minnesota; and Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.).
Janice K LaramyBrain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy (M.K., J.K.L., A.S.M., S.T., W.F.E.) and Clinical Pharmacology and Analytical Services Laboratory, Department of Experimental and Clinical Pharmacology (J.F.), University of Minnesota, Minneapolis, Minnesota; and Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.).
Afroz S MohammadBrain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy (M.K., J.K.L., A.S.M., S.T., W.F.E.) and Clinical Pharmacology and Analytical Services Laboratory, Department of Experimental and Clinical Pharmacology (J.F.), University of Minnesota, Minneapolis, Minnesota; and Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.).
Surabhi TaleleBrain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy (M.K., J.K.L., A.S.M., S.T., W.F.E.) and Clinical Pharmacology and Analytical Services Laboratory, Department of Experimental and Clinical Pharmacology (J.F.), University of Minnesota, Minneapolis, Minnesota; and Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.).
James FisherBrain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy (M.K., J.K.L., A.S.M., S.T., W.F.E.) and Clinical Pharmacology and Analytical Services Laboratory, Department of Experimental and Clinical Pharmacology (J.F.), University of Minnesota, Minneapolis, Minnesota; and Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.).
Jann N SarkariaBrain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy (M.K., J.K.L., A.S.M., S.T., W.F.E.) and Clinical Pharmacology and Analytical Services Laboratory, Department of Experimental and Clinical Pharmacology (J.F.), University of Minnesota, Minneapolis, Minnesota; and Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.).
William F ElmquistBrain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy (M.K., J.K.L., A.S.M., S.T., W.F.E.) and Clinical Pharmacology and Analytical Services Laboratory, Department of Experimental and Clinical Pharmacology (J.F.), University of Minnesota, Minneapolis, Minnesota; and Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.) elmqu011@umn.edu.
University of Minnesota · USAnalytical Services · USMayo Clinic · US
Funding
Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Douglas Yee · 1998 to 2026
$100.4MTrans Network ProjectU54CA210180 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI WHITE, FOREST M · 2016 to 2020
$10.2MTransport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHANG, JENNY C-N · 2016 to 2020
$9.3MPre-Clinical Novel Radiosensitizer Evaluation Program for Brain TumorsU01CA227954 · NCI · MAYO CLINIC ROCHESTER · PI SARKARIA, JANN N. · 2018 to 2022
$3.0MInfluence of Anti-Angiogenic Therapy on Drug Delivery to Brain TumorsR01NS077921 · NINDS · UNIVERSITY OF MINNESOTA · PI ELMQUIST, WILLIAM, SARKARIA, JANN N. · 2012 to 2016
$2.5MImproving Delivery of Molecularly-Targeted Therapy to Invasive Glioma CellsR01CA138437 · NCI · UNIVERSITY OF MINNESOTA · PI ELMQUIST, WILLIAM, OHLFEST, JOHN R · 2010 to 2014
$1.5MNCI NIH HHS P30 CA077598NCI NIH HHS R01 CA138437NCI NIH HHS U01 CA227954NCI NIH HHS U54 CA210180NCI NIH HHS U54 CA210181NINDS NIH HHS R01 NS077921
Abstract
Tyrosine kinase inhibitors that target the epidermal growth factor receptor (EGFR) have had success in treating EGFR-positive tumors, including non-small-cell lung cancer (NSCLC). However, developing EGFR inhibitors that can be delivered to the brain remains a challenge. To identify optimal compounds for brain delivery, eight EGFR inhibitors [afatinib, 6-[4-[(4-ethylpiperazin-1-yl)methyl]phenyl]-
Indexed as
AnimalsATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2Blood-Brain BarrierBrainErbB ReceptorsFemaleGlioblastomaMaleMiceProtein Kinase InhibitorsSignal TransductionAbcg2 protein, mouseATP-Binding Cassette TransportersATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2EGFR protein, mouseErbB ReceptorsProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.